# OnCo record nct02641847 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02641847/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02641847", "NCT02641847" ;
  schema:name "TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature"@en ;
  schema:description "A phase 2/3 trial of docetaxel, doxorubicin, epirubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by Fudan University, active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02641847/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02641847> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "tnbc-deep-dive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/cisplatin/> .